Katie, a dear friend and long-time client, recently called to share a transformative moment in her journey. Over the years, I’ve worked with her as a trainer, coach, and more recently, as a psychedelic guide and integration therapist. Currently, we’re focusing on helping her transition off Lexapro, a commonly prescribed SSRI, in preparation for a macro-dose psilocybin journey.
Katie had been taking 10 milligrams of Lexapro daily for twenty years but wanted to explore an alternative path—one that didn’t feel like it muted her emotions or dampened her ability to connect with herself. Over the past few months, we’ve been tapering her dosage carefully, reducing it by a quarter every week. Simultaneously, we introduced microdosing psilocybin, starting at 100 milligrams and gradually increasing to 200 milligrams over several weeks.
Today marked a turning point: Katie took a 300-milligram microdose and, for the first time, experienced perceptible effects. She described feeling amazing—elated, relaxed, and deeply hopeful. She texted me immediately to share her experience, and I called her to discuss how she was feeling.
Katie explained that the psilocybin felt like it was “putting her heart before her head.” She felt a profound sense of unity and connection, coupled with an emotional clarity she hadn’t experienced in years. While she noted that this dose left her feeling less sharp cognitively—a consideration for her professional responsibilities—it was a small trade-off for the overwhelming sense of possibility she felt.
This moment was particularly poignant because Katie had expressed concerns about coming off Lexapro. She feared that discontinuation might plunge her into a state of dread or emotional instability. Instead, the microdosing protocol has provided a bridge—offering her the emotional support and resilience she needed to navigate the tapering process.
Katie’s ability to articulate the benefits and sensations she’s experiencing is both exciting and promising. Her journey underscores the potential of microdosing psilocybin to help individuals not just transition off psychiatric medications like SSRIs, but also reconnect with emotions that have long been suppressed, masked, or dulled.
The Science Behind Microdosing Psilocybin
Katie’s experience aligns with a growing body of research exploring the therapeutic potential of psilocybin, particularly in addressing mood disorders and supporting transitions off SSRIs. While traditional antidepressants like Lexapro often work by blunting emotional extremes, psilocybin operates differently. It encourages emotional openness, neuroplasticity, and reconnection with feelings that are vital to healing and growth.
Emerging studies and anecdotal evidence suggest that microdosing psilocybin can:
Improve mood and emotional regulation.
Reduce symptoms of anxiety and depression.
Enhance a sense of connection and unity.
Support neurogenesis and help rewire unhelpful thought patterns.
Katie’s reflection about “putting her heart before her head” resonates with research showing that psilocybin helps quiet the brain’s Default Mode Network (DMN), which is often overactive in people with depression and anxiety. By calming this network, psilocybin allows for a shift from self-critical rumination to emotional clarity and presence.
Tapering Off SSRIs: A Delicate Balance
Transitioning off SSRIs requires a thoughtful and deliberate approach, as abrupt discontinuation can lead to withdrawal symptoms, mood swings, or a resurgence of depressive symptoms. In Katie’s case, combining a slow taper with psilocybin microdosing provided an added layer of emotional stability, helping her navigate the process with greater ease.
A Word of Caution
While Katie’s story is inspiring, it’s important to recognize that her journey was carefully tailored to her unique needs and circumstances. Microdosing psilocybin and tapering off SSRIs should never be attempted without professional guidance. The interaction between SSRIs and psilocybin is not fully understood, and individual responses can vary widely.
If you’re considering a similar path, consult with a qualified healthcare provider and ensure your decisions are informed by the latest research and safety protocols. Organizations like MAPS and Johns Hopkins University are leading the way in studying the therapeutic potential of psychedelics, and their findings can help guide safe and effective practices.
Katie’s experience is a testament to the possibilities that exist when traditional psychiatric care and emerging psychedelic therapies are thoughtfully integrated. As more research unfolds, we may continue to unlock new ways to support emotional healing, resilience, and hope.
Explore Psychedelic Assisted Behavior Change
Complete this short form to explore the possibility of embarking on a life-changing journey towards wellbeing, self-discovery, personal growth, and profound insight.
Share this post